Meningitis ACW135Y vaccine for travellers Practice Nursing Vol 21, No 9Adrienne Willcox
The increased incidence and epidemic occurrence of MenX meningitis in the African meningitis belt provides impetus for developing an effective vaccine for this pathogen to supplement the MenACW vaccines used in the region. A main prerequisite for successful introduction is that the vaccine will be aff...
The use of polysaccharide trivalent ACW vaccine for the control of epidemic meningococcal disease outbreaks in countries of the African meningitis belt. Re... The recommended strategy for EMD outbreak control in the African meningitis belt is based on reactive mass vaccination with the meningococcal PS...
GlaxoSmithKline Biologicals has produced a novel trivalent meningitis vaccine, ACW135, for use in African countries.Development-statusGlaxoSmithKlineMeningococcal-group-A-infections, preventionMeningococcal-group-C-infections, preventionMeningococcal-group-W-135-infections, prevention...
The increased incidence and epidemic occurrence of MenX meningitis in the African meningitis belt provides impetus for developing an effective vaccine for this pathogen to supplement the MenACW vaccines used in the region. A main prerequisite for successful introduction is that the vaccine will be aff...
The successful use of the trivalent polysaccharide vaccine ACW135 in Burkina Faso during the 2003 outbreak was essentially due to the high level of leadership demonstrated by the national authorities of Burkina Faso, the facilitating role of WHO, the effective coordination of partne...
The recent emergence of Neisseria meningitidis W135 as a cause of epidemic bacterial meningitis and the availability of a trivalent ACW135 vaccine have created a need for accurate and timely meningococcal serogroup determination for organization of epidemic vaccine response. The sensitivity and specificity...
Several reactive vaccination campaigns with ACW or ACWY polysaccharide vaccines have been conducted to control the spread of the outbreaks without much effect in preventing the recurrence of such outbreaks [63,64]. In addition, no polysaccharide vaccine is available for serogroup X. Since a conjugate...